Chromatin/Epigenetics
Chromatin/epigenetics inhibitors are compounds that modulate the structure and function of chromatin or interfere with epigenetic modifications, such as DNA methylation and histone modification. These inhibitors are essential tools for studying gene expression regulation and the role of epigenetics in diseases like cancer, neurological disorders, and developmental abnormalities. By targeting epigenetic processes, these inhibitors can alter gene expression patterns and offer new therapeutic avenues. At CymitQuimica, we provide a wide selection of high-quality chromatin/epigenetics inhibitors to support your research in molecular biology, genetics, and epigenetics.
Subcategories of "Chromatin/Epigenetics"
Found 2615 products of "Chromatin/Epigenetics"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
HDAC8-IN-2
HDAC8-IN-2 (5o) inhibits both smHDAC8 and hHDAC8 with IC50s of 0.27 μM, 0.32 μM, kills schistosome larvae, and lowers egg laying.Formula:C21H16N2O5Color and Shape:SolidMolecular weight:376.36Cenacitinib
CAS:Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.Formula:C19H19F2N7O3Color and Shape:SolidMolecular weight:431.40YLIU-4-105-1
CAS:YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.Formula:C32H34F3N7O2Color and Shape:SolidMolecular weight:605.65PFI-6-COOH
CAS:PFI-6-COOH (Compound 18) is a ligand for the eleven-nineteen leukemia (ENL) protein, and is utilized in the synthesis of the ENL PROTAC degrader MS41.Formula:C23H21N3O6Color and Shape:SolidMolecular weight:435.43HLCL-61
CAS:HLCL-61 is a premier small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5).Formula:C23H24N2OColor and Shape:SolidMolecular weight:344.45KAT6A-IN-1
CAS:KAT6A-IN-1 (compound 5) is an inhibitor of KAT6A.Formula:C23H27N5O5SColor and Shape:SolidMolecular weight:485.56KAT6A-IN-2
CAS:KAT6A-IN-2 (compound 7) is an inhibitor of KAT6A.Formula:C23H29N5O5SColor and Shape:SolidMolecular weight:487.57Trichostatin A S-isomer
CAS:Trichostatin A S-isomer, a HDAC 1, 3, 4, 6, 10 inhibitor with IC50 ~20 nM, has wide-ranging epigenetic effects.Formula:C17H22N2O3Purity:98%Color and Shape:SolidMolecular weight:302.37FT001
CAS:FT001: Oral BET Bromodomain inhibitor, IC50=0.46μM, suppresses MYC, anti-cancer, effective in vitro/vivo.Formula:C25H29N3O4SPurity:99.9%Color and Shape:SolidMolecular weight:467.58Ref: TM-T27392
1mg109.00€2mg163.00€5mg241.00€1mL*10mM (DMSO)284.00€10mg354.00€25mg532.00€50mg745.00€100mg1,018.00€500mg2,035.00€TYK2 ligand 2
CAS:TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.Formula:C24H20FN7O4Color and Shape:SolidMolecular weight:489.458Itareparib
CAS:Itareparib is a PARP inhibitor with demonstrated antitumor activity.Formula:C20H26FN3O2Color and Shape:SolidMolecular weight:359.438HDAC-IN-32
HDAC-IN-32, potent inhibitor: IC50—HDAC1 (5.2 nM), HDAC2 (11 nM), HDAC6 (28 nM). Effective anti-tumor and immunity-boosting traits.Formula:C20H23N3O3Color and Shape:SolidMolecular weight:353.41GSK3368715
CAS:GSK3368715 is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50sFormula:C20H38N4O2Purity:98%Color and Shape:SolidMolecular weight:366.54XY153
XY153 (8l) is a BD2 selective BET inhibitor targeting BRD4, 3 & 2 with IC50s: 0.79, 5.31 & 5.09 nM, useful in acute myeloid leukemia & cancer research.Formula:C33H34FN3O4Color and Shape:SolidMolecular weight:555.64AS2521780
CAS:AS2521780 is an inhibitor of PKCθ (IC50: 0.48 nM).Formula:C30H41N7OSPurity:98%Color and Shape:SolidMolecular weight:547.76I-BET282E
I-BET282E inhibits eight BET bromodomains (pIC50 6.4-7.7) with selectivity for other bromodomain proteins.Formula:C26H34N4O7SColor and Shape:SolidMolecular weight:546.64LSD1-IN-22
LSD1-IN-22: potent LSD1 inhibitor, K_i 98 nM, curbs cancer cell growth.Formula:C9H8BrF2NColor and Shape:SolidMolecular weight:248.07Pociredir
CAS:Pociredir (FTX-6058), a potent EED inhibitor (KD=0.163 nM), may help in SCD research.Formula:C22H18FN5O2Color and Shape:SolidMolecular weight:403.41PRMT5-MTA-IN-3
CAS:PRMT5-MTA-IN-3 (Compound P2A) is an orally active and selective inhibitor of protein arginine methyltransferase 5 (PRMT5). It inhibits the proliferation of MTAP-deficient colorectal cancer HCT-116 cell line with an IC50 value of 5 nM. PRMT5-MTA-IN-3 holds potential for research in cancers, particularly in MTAP-deficient tumors such as colorectal cancer, non-small cell lung cancer, and pancreatic cancer.Formula:C19H17F3N6O3Color and Shape:SolidMolecular weight:434.372GDC-0339
CAS:GDC-0339: oral Pim kinase inhibitor for multiple myeloma (Kis: Pim1 - 0.03 nM, Pim2 - 0.1 nM, Pim3 - 0.02 nM), well-tolerated.Formula:C20H22F3N7OSColor and Shape:SolidMolecular weight:465.5SIRT6 activator 2
CAS:SIRT6 activator2 (compound 31) is a sirtuin6 activator known for its anti-lipid accumulation properties. It significantly downregulates LXR, SREBP-1c, and their target genes, making it valuable for research into lipid metabolism-related diseases.Formula:C23H23N3O6Color and Shape:SolidMolecular weight:437.45LSD1-IN-15
LSD1-IN-15 inhibits LSD1, MAO-A/B with IC50s: 0.149, 0.028, 0.327 μM; arrests LNCaP cancer cell growth, IC50 9.9 μM.Formula:C22H20N2OColor and Shape:SolidMolecular weight:328.41Purinostat
CAS:Purinostat is a selective inhibitor of HDACI/IIb with potential anti-leukemic properties. Its mesylate form, Purinostat mesylate, is effective at inhibiting the survival of Ph+ leukemic cells and CD34+ leukemic cells derived from CML patients. Purinostat mesylate targets HDACI/IIb, impacting several crucial factors for leukemia stem cell (LSC) survival, such as c-Myc, β-Catenin, E2f, Ezh2, Alox5, and mTOR. Additionally, Purinostat mesylate enhances glutamate metabolism in LSCs by increasing GLS1.Formula:C23H26N10O3Color and Shape:SolidMolecular weight:490.518Sirtuin-IN-2
Sirtuin-IN-2 (compound 20) is an inhibitor of Sirtuin5, a key target in leukemia and breast cancer.Formula:C28H46N8O6SColor and Shape:SolidMolecular weight:622.78MC3138
CAS:MC3138 is a selective SIRT5 activator showing anti-tumor effects in PDAC cells.Formula:C25H25NO6Purity:99.57%Color and Shape:SolidMolecular weight:435.47CREB-IN-1 TFA
CREB-IN-1 TFA: Potent oral CREB inhibitor, IC50 of 0.18 μM, suppresses breast cancer cell growth.Color and Shape:SolidAMPK activator 16
CAS:AMPK activator16 (compound 6) functions as an AMP-activated protein kinase (AMPK) inhibitor. It interacts effectively with crucial AMPK residues, significantly activating the enzyme. In N2a cells, AMPK activator16 enhances the expression of phosphorylated AMPK (p-AMPK) and its downstream signaling proteins, such as phosphorylated ACC (Acetyl-CoA Carboxylase) and phosphorylated raptor (p-raptor).Formula:C23H20ClNO5SColor and Shape:SolidMolecular weight:457.927LSD1-IN-39
CAS:LSD1-IN-39 (Compound 14) is a reversible inhibitor of LSD1 with an IC50 of 0.18 μM, showing broad-spectrum antiproliferative activity against cancer cells, inhibiting HepG2 cell migration, and suppressing epithelial-mesenchymal transition. Additionally, LSD1-IN-39 exhibits antitumor activity in mouse models.Formula:C25H30N2O7Color and Shape:SolidMolecular weight:470.515DDO-3055
CAS:DDO-3055 is an orally active PHD2 inhibitor utilized in studies related to anemia associated with chronic kidney disease.Formula:C17H13ClN2O5Color and Shape:SolidMolecular weight:360.749JTZ-951 HCl
CAS:JTZ-951 is a potent and orally active inhibitor of hypoxia inducible factor prolyl hydroxylase (PHD).Formula:C17H17ClN4O4Purity:98%Color and Shape:SolidMolecular weight:376.79HIF-2α-IN-5
CAS:HIF-2α-IN-5 is a potent HIF-2α inhibitor with an IC 50 of < 50 nM [1].Formula:C15H12F4O3S2Color and Shape:SolidMolecular weight:380.38lirucitinib
CAS:Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.Formula:C16H25N5OSColor and Shape:SolidMolecular weight:335.468HDAC6-IN-51
CAS:HDAC6-IN-51 (Compound 7e) is a selective inhibitor of HDAC6, exhibiting an IC50 value of 42.9 nM. This compound demonstrates effective anti-pulmonary fibrosis activity.Formula:C24H24ClN5O3Color and Shape:SolidMolecular weight:465.93HDAC1-IN-3
HDAC1-IN-3 is a potent inhibitor of Pf HDAC1.Formula:C22H24ClN7O2Color and Shape:SolidMolecular weight:453.92DS79932728
CAS:DS79932728 is an orally active inhibitor of G9a and GLP, with IC50 values of 12.6 nM and 75.7 nM, respectively. It induces the production of γ-globin, thereby increasing fetal hemoglobin (HbF) levels. In cynomolgus monkey models, DS79932728 enhances the proportion of F-reticulocytes (F-rets) and shows good oral absorption characteristics.Formula:C19H25N3OColor and Shape:SolidMolecular weight:311.421PRMT5-IN-48
CAS:PRMT5-IN-48 (compound D3) is an orally active PRMT5 inhibitor with an IC50 of 20.7 nM, displaying antitumor activity. It effectively suppresses the growth of various cancer cells, induces apoptosis, and causes cell cycle arrest at the G0/G1 phase. PRMT5-IN-48 is applicable for research in non-Hodgkin's lymphoma (NHL).Formula:C30H37N5O3Color and Shape:SolidMolecular weight:515.646HDAC11-IN-2
CAS:HDAC11-IN-2 (compound B6) is a highly selective inhibitor of Histone Deacetylase 11 (HDAC11). It demonstrates IC50 values of 51.1 ×10^-3 μM for HDAC11 and 5 μM for HDAC8. HDAC11-IN-2 reduces de novo lipogenesis (DNL) and enhances fatty acid oxidation, which alleviates hepatic lipid accumulation and pathological symptoms in MASLD mice. By inhibiting HDAC11, HDAC11-IN-2 enhances the phosphorylation of AMPKα1 at the Thr172 site, thereby modulating de novo lipogenesis and fatty acid oxidation in the liver.Formula:C25H35N3O3Color and Shape:SolidMolecular weight:425.564Milpecitinib
CAS:Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.Formula:C20H20N4O2SColor and Shape:SolidMolecular weight:380.463SIRT-IN-6
CAS:SIRT-IN-6 (Compound 14) is a pan-inhibitor of SIRT1/2/3 with an IC50 value of >50 μM. It shows potential as a research agent for studies involving metabolic disorders, inflammation, cancer, and neurodegenerative diseases.Formula:C7H4ClN3OSColor and Shape:SolidMolecular weight:213.644PHD2-IN-4
CAS:PHD2-IN-4 (compound 1) is an inhibitor of PHD2, with an IC50 of 4 nM. It is utilized in research related to chronic kidney disease.Formula:C21H19N5O3Color and Shape:SolidMolecular weight:389.407HDAC-IN-87
CAS:HDAC-IN-87 (Compound XII6) is a non-selective HDAC inhibitor with pIC50 values of 6.9 for HDAC4 and 5.8 for HDAC6. It exhibits fungicidal activity against P. sorghi and P. pachyrhizi. The acute oral LD50 in both male and female rats is greater than 500 mg/kg.Formula:C13H7F5N4O2SColor and Shape:SolidMolecular weight:378.277BET/Aurora kinase-IN-1
CAS:BET/Aurora kinase-IN-1 (Compound 38) is a dual inhibitor of BET and Aurora kinases. It exhibits antiproliferative activity against various tumor cell lines and demonstrates significant antitumor efficacy in xenograft models of renal cell carcinoma and colon cancer, with tumor growth inhibition (TGI) rates of 45.99% and 53.06%, respectively.Formula:C25H30FN7OColor and Shape:SolidMolecular weight:463.55(rac)-Talazoparib
CAS:(rac)-Talazoparib ((rac)-BMN-673) (Compound 47) is an orally active inhibitor of PARP1/2, with Ki values of 1.2 nM and 0.87 nM, respectively. It inhibits cellular PARylation at an EC50 of 2.51 nM. This compound leads to the accumulation of DNA damage and suppresses the proliferation of BRCA1/2-mutated MX-1 and Capan-1 cells, with IC50 values of 0.3 nM and 5 nM, respectively. Additionally, (rac)-Talazoparib exhibits antitumor activity in mouse models.Formula:C19H14F2N6OColor and Shape:SolidMolecular weight:380.351NSD2-PWWP1-IN-1
CAS:NSD2-PWWP1-IN-1 (compound 31) is a potent inhibitor of NSD2-PWWP1 with an IC50 value of 0.64 µM, demonstrating potential applications in cancer research.Formula:C28H30N4Color and Shape:SolidMolecular weight:422.565JPHM-2-167
CAS:PHM-2-167 (Compound 11) is a selective inhibitor of the prolyl hydroxylase domain enzyme (PHD). It inhibits PHD2 and PHD3 with IC50 values of 0.253 μM and 3.95 μM, respectively. PHM-2-167 is applicable for research in chronic kidney disease.Formula:C30H28N6O2Color and Shape:SolidMolecular weight:504.582O6BTG-C8-αGlu
CAS:O6BTG-C8-αGlu is an O6-methylguanine-DNA methyltransferase (MGMT) inhibitor with an IC50 of 0.45 μM. At a concentration of 0.1 μM, it fully inhibits MGMT in HeLaS3 cells and demonstrates no cytotoxicity even at prolonged high doses (up to 20 μM). This compound is suitable for research on MGMT-related cancers.Formula:C24H34BrN5O7SColor and Shape:SolidMolecular weight:616.525Balomenib
CAS:Balomenib is an inhibitor of the menin-MLL interaction, effectively blocking the men1-MLL4-43 interaction with an IC50 of less than 0.075 μM. It inhibits cell growth in MV4-11 (CC50 < 0.1 μM), MOLM-13 (CC50 0.1~0.5 μM), and HEK293 (CC50 < 2 μM) cells. Balomenib also exhibits antitumor activity.Formula:C33H34F3N7O2Color and Shape:SolidMolecular weight:617.6646K465
CAS:6K465 is a potent Aurora A kinase inhibitor that reduces c-MYC and N-MYC oncoproteins, showing antiproliferative effects in SCLC and breast cancer cell lines.Formula:C26H33ClFN9OPurity:99.78%Color and Shape:SolidMolecular weight:542.05BSI-401
CAS:BSI-401 is an oral inhibitor of PARP-1. It can inhibit pancreatic cancer either when used alone or in synergy with Oxaliplatin.Formula:C9H4INO4Color and Shape:SolidMolecular weight:317.037W4275
CAS:W4275 (Compound 42) is a selective NSD2 inhibitor with oral activity and an IC50 of 17 nM. It exhibits antiproliferative activity, with an IC50 of 230 nM against RS411 cells, and significantly inhibits tumor growth in an RS411 tumor xenograft model. Pharmacokinetic analysis in mice shows that W4275 has a favorable oral bioavailability (F is 27.34%). W4275 holds potential for use in cancer research.Formula:C25H36N6O3Color and Shape:SolidMolecular weight:468.59
